American Oncology Network, Inc.
Healthcare · Services-Health Services · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|
| Revenue | $1.76B | $1.28B | $1.15B | $943.7M | — |
| Operating income | −$17.4M | −$49.2M | $5.6M | $911,000 | −$834 |
| Net income | −$27.0M | −$5.2M | $10.5M | $8.4M | −$834 |
| Total assets | $470.3M | $374.5M | $326.2M | $334.9M | $9,572 |
| Total liabilities | $362.3M | $303.7M | $264.2M | $22.3M | $10,406 |
| Equity | −$46.2M | −$161.7M | −$14.2M | −$20.9M | −$834 |
| EPS (diluted) | $-0.89 | $-1.36 | $0.00 | $0.00 | — |
| Shares out. | 37.5M | 10.1M | 0 | 0 | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- −1.0%
- Net margin
- −1.5%
- Return on equity
- 58.3%
- Return on assets
- −5.7%
- Return on capital (ROCE)
- −6.9%
- Liabilities / assets
- 77.0%
- Debt / equity
- —
- Book value / share
- $-1.23
- Revenue growth (YoY)
- 37.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- 0.51distress
- Accruals / assets
- −4.7%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 16, 2022
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2022
- NT 10-Qmissed a reporting deadline ↗Nov 16, 2021
- NT 10-Qmissed a reporting deadline ↗Aug 17, 2021
- NT 10-Qmissed a reporting deadline ↗May 18, 2021
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Valle WilliamDirector | Jul 16, 2024 | Grant | 5,000 | $0.00 |
| Fluegel Bradley MDirector | Jul 16, 2024 | Grant | 5,000 | $0.00 |
| Divers StephenOfficer — Chief Medical Officer | Jul 16, 2024 | Grant | 36,000 | $0.00 |
| Mallon EricaOfficer — General Counsel | Jul 16, 2024 | Grant | 36,000 | $0.00 |
| Afshar DavidOfficer — Chief Financial Officer | Jul 16, 2024 | Grant | 150,000 | $0.00 |
| Schonherz ToddOfficer — Chief Executive Officer | Jul 16, 2024 | Grant | 300,000 | $0.00 |
| Divers StephenOfficer — Chief Medical Officer | May 24, 2024 | Buy | 5,000 | $2.15 |
| Schonherz ToddOfficer — Chief Executive Officer | May 21, 2024 | Buy | 4,000 | $1.87 |
| Fluegel Bradley MDirector | May 4, 2024 | Grant | 14,981 | $0.00 |
| Valle WilliamDirector | May 4, 2024 | Grant | 14,981 | $0.00 |
| Divers StephenOfficer — Chief Medical Officer | Mar 20, 2024 | Tax withholding | 8,554 | $5.70 |
| Divers StephenOfficer — Chief Medical Officer | Mar 19, 2024 | Grant | 59,500 | $5.69 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · New financial obligationDec 19, 2024
- Shareholder voteDec 18, 2024
- Entered a material agreementJul 25, 2024
- Director / officer changeJun 3, 2024
- Delisting / listing-standard noticeMay 21, 2024
- Results of operationsMay 15, 2024
- Director / officer changeMay 3, 2024
- Director / officer changeApr 22, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.